Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword

Betul Oran; Naval Daver

doi:10.1016/j.bbmt.2018.11.026

Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	e1-e2
Journal	Biology of Blood and Marrow Transplantation
Volume	25
Issue number	1
DOIs	https://doi.org/10.1016/j.bbmt.2018.11.026
State	Published - Jan 2019

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2018.11.026

Cite this

@article{139a1a7d766245c991ae205418e40bbc,

title = "Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword",

author = "Betul Oran and Naval Daver",

note = "Funding Information: Financial disclosure: N.D. received research funding from BMS, Pfizer, Incyte, Servier, Abbvie, Daiichi-Sankyo, Immunogen, Genentech and consulting honoraria from Pfizer, Daiichi-Sankyo, Astellas, Abbvie, Genentech, Jazz, Servier, Incyte, and Immunogen. B.O. received research funding from Celgene, Astex, and AROG Pharmaceuticals. Funding Information: Financial disclosure: N.D. received research funding from BMS , Pfizer , Incyte , Servier , Abbvie , Daiichi-Sankyo , Immunogen , Genentech and consulting honoraria from Pfizer, Daiichi-Sankyo, Astellas, Abbvie, Genentech, Jazz, Servier, Incyte, and Immunogen. B.O. received research funding from Celgene, Astex, and AROG Pharmaceuticals . ",

year = "2019",

month = jan,

doi = "10.1016/j.bbmt.2018.11.026",

language = "English (US)",

volume = "25",

pages = "e1--e2",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant

T2 - The Double-Edge Sword

AU - Oran, Betul

AU - Daver, Naval

N1 - Funding Information: Financial disclosure: N.D. received research funding from BMS, Pfizer, Incyte, Servier, Abbvie, Daiichi-Sankyo, Immunogen, Genentech and consulting honoraria from Pfizer, Daiichi-Sankyo, Astellas, Abbvie, Genentech, Jazz, Servier, Incyte, and Immunogen. B.O. received research funding from Celgene, Astex, and AROG Pharmaceuticals. Funding Information: Financial disclosure: N.D. received research funding from BMS , Pfizer , Incyte , Servier , Abbvie , Daiichi-Sankyo , Immunogen , Genentech and consulting honoraria from Pfizer, Daiichi-Sankyo, Astellas, Abbvie, Genentech, Jazz, Servier, Incyte, and Immunogen. B.O. received research funding from Celgene, Astex, and AROG Pharmaceuticals .

PY - 2019/1

Y1 - 2019/1

UR - http://www.scopus.com/inward/record.url?scp=85057711995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057711995&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.11.026

DO - 10.1016/j.bbmt.2018.11.026

M3 - Comment/debate

C2 - 30500441

AN - SCOPUS:85057711995

SN - 1083-8791

VL - 25

SP - e1-e2

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 1

ER -

Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this